activity is expected. The failure of F(ab')2 fragments to bind is unexpected, pointing to a critical role for the Fe portion of the IgG molecule in stabilising antibody interaction. The Fe portion can contribute to anti-DNA by inducing a conformational change in the binding sites; contacting DNA; or forming Fc:Fc interactions to increase valency. This binding pattern can be called Fe-dependent monogamous bivalency. The findings suggest that agents that affect the Fe portion may be useful to therapeutically inhibit anti-DNA interactions.

Background Although excess levels of B cell activating factor of the TNF family (BAFF, also known as BlyS) have been implicated in the pathogenesis of SLE, how excess BAFF promotes breaks in B cell tolerance is not completely understood. Transgenic mice (Tg) overexpressing BAFF develop an autoimmune disease resembling human SLE. BAFF binds to distinct receptors expressed on B cells, the BAFF receptor (BAFF-R) and transmembrane activator and CAML interactor (TACI). Since BAFF-R deletion results in loss of mature B cells, BAFF-R-dependent signals are presumed to explain BAFF-mediated autoimmunity. However, potential important roles for TACI in lupus pathogenesis have not been addressed.

Materials and methods After crossing BAFF-Tg and Tacif−/− mice, we used standard immunologic techniques to test the impact of TACI on BAFF-driven autoimmunity.

Results Despite prior evidence of a negative role for TACI in B cell activation, we discovered that TACI deletion resulted in a striking loss of class-switched serum autoantibodies. Loss of serum autoantibodies also correlated with protection from immune-complex glomerulonephritis in Tacif−/−BAFF-Tg mice. Importantly, lack of autoimmunity was not explained by alterations in peripheral B cell development, since both BAFF-Tg and Tacif−/−BAFF-Tg mice exhibited similar B cell hyperplasia, with equivalent expansion of the follicular (FM) and marginal zone (MZ) compartments. Rather, whereas surface TACI expression is usually limited to mature B cells, we discovered that excess BAFF integrates with dual B cell receptor (BCR)- and MyD88-dependent signals to promote TACI upregulation on transitional B cells. The novel TACI−/− subset of transitional B cells from BAFF-Tg mice are characterised by an activated, cycling phenotype and spontaneous GC formation in vivo. This finding suggested that other cytokines promote B cell activation in the WAS chimaera model. Notably, previously defined CD4+ T cell activation and T follicular helper cell formation via MHC Class II (MHC-II)-dependent antigen presentation. In addition, activated T cells exhibited prominent IFN-γ production that was lost following B cell-intrinsic MHC-II deletion, suggesting a direct role for IFN-γ in promoting autoimmune GC formation. Strikingly, B cell-intrinsic deletion of the IFN-γ receptor was sufficient to abrogate spontaneous GCs, class-switched autoantibodies and systemic autoimmunity. Mechanistically, although IFN-γ receptor signals increased B cell T-bet expression, B cell-intrinsic deletion of T-bet exerted an isolated impact on class-switch recombination to pathogenic IgG2c autoantibody subclasses without impacting GC development. Rather, in both murine and human B cells, IFN-γ synergized with BCR, TLR and/or CD40 activation signals to promote cell-intrinsic BCL-6 expression. Finally, IFN-γ driven BCL-6 expression in B cells was blocked using clinically-relevant Janus kinase inhibitors, ruxolitinib and tofacitinib.
Conclusions Our study demonstrates that B cell-intrinsic IFN-γ receptor signals promote lupus pathogenesis via formation of spontaneous, autoimmune GCs. In addition, we have uncovered a novel cell-intrinsic program whereby IFN-γ, together with BCR-, TLR- and/or CD40 signals, orchestrates B cell expression of the GC master transcription regulator BCL-6. Our combined findings suggest that this IFN-γ signalling program may be a potential therapeutic target in SLE.

Acknowledgements This work was supported by the National Institutes of Health under award numbers: R01HL075453 (DJR), R01AI084457 (DJR), R01AI071163 (DJR), DP1DK097672 (DJR) and K08AI112993 (SWJ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional support provided by the Benaroya Family Gift Fund (DJR); by the ACR REF Rheumatology Scientist Development Award (SWJ); and by the Arnold Lee Smith Endowed Professorship for Research Faculty Development (SWJ).

Abstract A19 Figure 1 Exemplary data showing that treatment with 2 DG reverses ongoing autoimmune disease of BXSB.Yaa mice. (A) Schematic of the therapeutic approach. (B) BXSB.Yaa mice were aged to 12 wks. FACS analysis of blood CD4+ T cell and B cells 0, 4, 8 of treatment and 12 wks (4 wks after treatment was withdrawn). (C) Analysis of CD4+ splenic CD4+ T cells and B cells 8 wks after treatment. (D) Survival of mice after withdrawal of treatment*. P <0.05.

Metabolic inhibition by 2-deoxyglucose prevents and reverses lupus in mice
Thomas J Sproule, John Wilson, Elisabeth Adkins, Byron P Crocker, Laurence Morel, Derry C Roopenian.
The Jackson Laboratory, Bar Harbour, ME, USA; Department of Pathology, University of Florida, Gainesville, FL, USA
10.1136/lupus-2016-000179.18

Background Glucose is a primary substrate for cellular respiration. Glucose utilisation increases in highly metabolic cells including activated, proliferating T cells and B cells as well as cancers. Lupus is a disorder in which autoreactive CD4+ T cell and B cells that deviate from normal homeostasis by their uncontrolled proliferation and differentiation to effector cells. Therapeutic limitation of glycolysis is therefore an attractive approach for attenuating the highly energetic, pathogenic processes inherent to lupus. Here we investigate the potential of several metabolic inhibitors that target early and downstream aspects of cellular respiration to identify inhibitors that show potential in the prevention and treatment of lupus.

Materials and methods Metabolic inhibitors included: 1) a classic glycolysis inhibitor, 2 deoxyglucose (2 DG); 2) a mitochondrial complex I inhibitor/AMPK activator metformin (MET); 3) an mTOR inhibitor, rapamycin (RAPA); and 3) a pyruvate dehydrogenase kinase inhibitor, dichloroacetate (DCA). The drugs were provided in drinking water or mouse chow for 4–8 wks. NZB X NZW F1 (BWF1) and BXSB.Yaa mouse models of lupus were evaluated in prevention studies and in treatment of mice documented to be undergoing autoimmune disease. Longitudinal and terminal immunophenotyping was performed using flow cytometric, serological, histopathological analyses.

Results 2 DG, MET, DCA and RAPA, and combinations thereof were applied prior to the onset of autoimmune disease to BWF1 and BXSB. Yaa mice. 2 DG showed minimal effects and RAPA resulted in partial attenuation. In contrast, 2 DG acted potently to abrogate multiple disease biomarkers while not causing immunodeficiency. Given the strong immunologically normalising effects of 2 DG in disease prevention, we performed therapeutic interventions in which 2 DG was supplied for 8 weeks to already diseased BWF1 and BXSB.Yaa mice. Within 4 weeks of treatment, 2 DG normalised all cellular, serological and pathological features characteristic of the BWF1 and BXSB. Yaa lupus like syndromes. Furthermore, the lifespans of BXSB. Yaa mice were extended after withdrawal of treatment (Figure 1).

Conclusions Overall, the results highlight the potent and remarkable normalising effect of 2 DG in the prevention and treatment lupus-like autoimmune disease in mouse models with differing genetic and mechanistic etiologies. Given findings, we propose that therapeutic inhibition of early steps in glycolysis, as exemplified by 2 DG, has broad potential for the treatment of multiple autoimmune disorders. Our current efforts are focused on: 1) the potential of 2 DG in treatment of other autoimmune severe diseases; and 2) evaluation of potential downsides of metabolic inhibition by 2 DG and other inhibitors of glycolysis.

Acknowledgements This work was supported by the Alliance for Lupus Research.

Defective BCR induced apoptosis linked to elevated levels of 9-O-acetylated sialyl gangliosides on B cells in lupus provides a potential therapeutic target for lupus
Xin Ka, Vinay S Maharaj, Kendra Taylor, Shiv Pillai.
Ragon Institute of MGH, MIT and Harvard, Cambridge Massachusetts, Massachusetts General Hospital, Harvard Medical School, Boston USA
10.1136/lupus-2016-000179.19

Abstract AI-20 Figure 1 A schematic of the therapeutic approach. B) BXSB.Yaa mice were aged to 12 wks. FACS analysis of blood CD4+ T cell and B cells 0, 4, 8 of treatment and 12 wks (4 wks after treatment was withdrawn). (C) Analysis of CD4+ splenic CD4+ T cells and B cells 8 wks after treatment. (D) Survival of mice after withdrawal of treatment*. P ≤0.05.

Defective BCR induced apoptosis linked to elevated levels of 9-O-acetylated sialyl gangliosides on B cells in lupus provides a potential therapeutic target for lupus